Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has a new office in South San Francisco’s biotech hub at Oyster Point, where it says it can better serve current and future clients on the US west coast.
The company has grown in the previous year, having recently expanded operations at its headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site at the research campus at Alderley Park, UK.
Having first established a US office in 2019 in the Cambridge–Boston biotech hub in Massachusetts, Sygnature says this expansion of its US presence with a second office will help meet growing demand from its US customers, which range from big pharma through to small seed-funded biotechnology companies.
Simon Hirst, Sygnature’s CEO and Founder, said: “Our very first client was actually from the US, and it remains a very significant market for us, both now and in our future strategy. It’s fantastic to have a base on the west coast, and in such a vibrant hub for the life sciences community. Our approach to drug discovery is based on true collaboration and partnership with our clients and having a physical presence near to many of them helps us to work the way we believe in, strengthening those ties and relationships that lead to success.”
Image credit: Patrick Tomasso
